Ovide ® (malathion) Lotion, 0.5%

Manufacturer
Sun Pharmaceutical Industries, Inc. | Suven Life Sciences Limited
Effective date
2026-07-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
daily-update
Hydrated at
2026-07-18 05:11:15

Label at a glance#

ProductOvide
Active ingredientMALATHION
Label structure13 sections

Indications and uses

OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

Dosage and administration

Apply OVIDE Lotion on DRY hair in amount just sufficient to thoroughly wet the hair and scalp. Pay particular attention to the back of the head and neck while applying OVIDE Lotion. Wash hands after applying to scalp. Allow hair to dry naturally - use no electric heat source, and allow hair to remain uncovered. After 8 to 12 hours, the hair should be shampooed. Rinse and use a fine - toothed (nit) comb to remove d...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

NDC 51672-5293-4

Rx Only

For topical use only. Not for oral or ophthalmic use.

DESCRIPTION

DESCRIPTION SECTION

OVIDE Lotion contains 0.005 g of malathion per mL in a vehicle of isopropyl alcohol (78%), terpineol, dipentene, and pine needle oil. The chemical name of malathion is (±) - [(dimethoxyphosphinothioyl) - thio] butanedioic acid diethyl ester. Malathion has a molecular weight of 330.36, represented by C 10H 19O 6PS 2, and has the following chemical structure:

Chemical Structure
Chemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity in vivo.Inadvertent transdermal absorption of malathion has occurred from its agricultural use. In such cases, acute toxicity was manifested by excessive cholinergic activity, i.e., increased sweating, salivary and gastric secretion, gastrointestinal and uterine motility, and bradycardia (see OVERDOSAGE). Because the potential for transdermal absorption of malathion from OVIDE Lotion is not known at this time, strict adherence to the dosing instructions regarding its use in children, method of application, duration of exposure, and frequency of application is required.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis(head lice and their ova) of the scalp hair.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

OVIDE Lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. OVIDE Lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle.

WARNINGS

WARNINGS SECTION

  1. OVIDE Lotion is flammable.The lotion and wet hair should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. Allow hair to dry naturally and to remain uncovered after application of OVIDE Lotion.
  2. OVIDE Lotion should only be used on children under the direct supervision of an adult.
  3. If OVIDE Lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists.
  4. If skin irritation occurs, discontinue use of product until irritation clears. Reapply the OVIDE Lotion, and if irritation reoccurs, consult a physician.
  5. Chemical burns including second-degree burns and stinging sensations may occur with the use of OVIDE Lotion.

General

GENERAL PRECAUTIONS SECTION

Keep out of reach of children. Close eyes tightly during product application. If accidentally placed in the eye, flush immediately with water. Use only on scalp hair.

Information to Patients

INFORMATION FOR PATIENTS SECTION

  1. OVIDE Lotion is flammable.The lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. The person applying OVIDE Lotion should wash hands after application. Allow hair to dry naturally and to remain uncovered after application of OVIDE Lotion.
  2. OVIDE Lotion should only be used on children under the direct supervision of an adult. Children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet.
  3. In case of accidental ingestion of OVIDE Lotion by mouth, seek medical attention immediately.
  4. If you are pregnant or nursing, you should contact your physician before using OVIDE Lotion.
  5. If OVIDE Lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists or if visual changes occur.
  6. If skin irritation occurs, wash scalp and hair immediately. If the irritation clears, OVIDE Lotion may be reapplied. If irritation reoccurs, consult a physician.
  7. Burns and stinging sensations may occur when using OVIDE Lotion.
  8. Apply OVIDE Lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. Pay particular attention to the back of the head and neck when applying OVIDE Lotion. Anyone applying OVIDE Lotion should wash hands immediately after the application process is complete.
  9. Allow hair to dry naturally and to remain uncovered. Shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing.
  10. Rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs.
  11. If lice are still present after 7 - 9 days, repeat with a second application of OVIDE Lotion.
  12. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Laboratory Tests

LABORATORY TESTS SECTION

There are no special laboratory tests needed in order to use this medication.

Carcinogenesis , Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, mutagenesis and impairment of fertility have not been studied with OVIDE Lotion (0.5% pharmaceutical grade malathion). However, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in B6C3F1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. These tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. Based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of OVIDE Lotion, assuming 100% bioavailability. Actual systemic exposures are expected to be less than 10% of the administered dose.

The malathion of greater than pharmaceutical-grade purity used in OVIDE Lotion has not been tested for genotoxicity. The technical-grade malathion (95% pure) was found to be negative in Salmonella typhimurium, equivocally positive in the mouse lymphoma cell assay, and positive in in vitrochromosomal aberration and sister chromatid exchange assays. Fifteen separate in vitrogene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. Both technical grade (94–96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitroin human and hamster cell lines. In vivochromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivochromosomal aberration study of >99% pure malathion was reported to be negative. Furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. Lack of details makes independent evaluation of the results of these assays impossible. Ashby and Purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion.

Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility.

Pregnancy

PREGNANCY SECTION

Pregnancy Category B

TERATOGENIC EFFECTS SECTION

There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Malathion in an acetone vehicle has been reported to be absorbed through human skin to the extent of 8% of the applied dose. However, percutaneous absorption from the OVIDE ®(malathion) Lotion, 0.5% formulation has not been studied, and it is not known whether malathion is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OVIDE Lotion is administered to (or handled by) a nursing mother.

Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of OVIDE Lotion in children less than 6 years of age has not been established via well-controlled trials.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Malathion has been shown to be irritating to the skin and scalp. Other adverse reactions reported are chemical burns including second-degree burns. Accidental contact with the eyes can result in mild conjunctivitis.

It is not known if OVIDE Lotion has the potential to cause contact allergic sensitization.

OVERDOSAGE

OVERDOSAGE SECTION

Consideration should be given, as part of the treatment program, to the high concentration of isopropyl alcohol in the vehicle.

Malathion, although a weaker cholinesterase inhibitor than some other organophosphates, may be expected to exhibit the same symptoms of cholinesterase depletion after accidental ingestion orally. If accidentally swallowed, vomiting should be induced promptly or the stomach lavaged with 5% sodium bicarbonate solution.

Severe respiratory distress is the major and most serious symptom of organophosphate poisoning requiring artificial respiration, and atropine may be needed to counteract the symptoms of cholinesterase depletion.

Repeat analyses of serum and RBC cholinesterase may assist in establishing the diagnosis and formulating a long - range prognosis.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

  1. Apply OVIDE Lotion on DRYhair in amount just sufficient to thoroughly wet the hair and scalp. Pay particular attention to the back of the head and neck while applying OVIDE Lotion. Wash hands after applying to scalp.
  2. Allow hair to dry naturally - use no electric heat source, and allow hair to remain uncovered.
  3. After 8 to 12 hours, the hair should be shampooed.
  4. Rinse and use a fine - toothed (nit) comb to remove dead lice and eggs.
  5. If lice are still present after 7 - 9 days, repeat with a second application of OVIDE Lotion.

Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Clinical Studies

CLINICAL STUDIES SECTION

Two controlled clinical trials evaluated the pediculicidal activity of OVIDE Lotion. Patients applied the lotion to the hair and scalp in quantities, up to a maximum of 2 fl. oz., sufficient to thoroughly wet the hair and scalp. The lotion was allowed to air dry and was shampooed with Prell shampoo 8 to 12 hours after application. Patients in both the OVIDE Lotion group and in the vehicle group were examined immediately after shampooing, 24 hours after, and 7 days after for the presence of live lice. Results are shown in the following table:

Number of Patients without Live Scalp Lice
TreatmentImmediately After24 Hrs. After7 Days After
OVIDE Lotion129/129122/129114/126
OVIDE Vehicle105/10563/10531/105

The presence or absence of ova at day 7 was not evaluated in these studies. The presence or absence of live lice or ova at 14 days following treatment was not evaluated in these studies. The residual amount of malathion on hair and scalp is unknown.

HOW SUPPLIED

HOW SUPPLIED SECTION

OVIDE ®(malathion) Lotion, 0.5%, is supplied in bottles of 2 fl. oz. (59 mL) NDC 51672-5293-4.

STORAGE AND HANDLING SECTION

Stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]

Flammable. Keep away from heat and open flame.

SPL UNCLASSIFIED SECTION

Manufactured for:
TaroPharma ®
a division of Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532
Manufactured By: Suven Life Sciences Limited, Plot No. 262-271, IDA, Pashamylaram, Sangareddy District,
Telangana, 502307 India.

Ovide ®and TaroPharma ®are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates.

Lb30005-4-02
Issued: March, 2017
0317-2

PRINCIPAL DISPLAY PANEL - 59 mL Bottle Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51672-5293-4

OVIDE ®
(malathion)
LOTION, 0.5%

In isopropyl alcohol (78%),
terpineol, dipentene and
pine needle oil.

PEDICULICIDE/OVICIDE

WARNING:
Contains flammable alcohol.
Avoid smoking, open flame and hair dryers.
Allow hair to dry naturally and uncovered.

Rx Only

Taro Pharma ®

2 fl. oz. (59 mL)

PRINCIPAL DISPLAY PANEL - 59 mL Bottle Carton
PRINCIPAL DISPLAY PANEL - 59 mL Bottle Carton

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6d2da11d-2f7e-d69f-1620-73a34452e2e3Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51672-5293-4ML - Milliliter51672-5293ff47ef52-3c88-4677-8923-3a3b5fa80fe912014-06-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
MalathionACTIVE INGREDIENTU5N7SU872W1
MalathionACTIVE MOIETYU5N7SU872W1
isopropyl alcoholINACTIVE INGREDIENTND2M4163021
limonene, (+/-)-INACTIVE INGREDIENT9MC3I344471
pine needle oil (pinus sylvestris)INACTIVE INGREDIENT5EXL5H740Y1
terpineolINACTIVE INGREDIENTR53Q4ZWC991

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51672-529351672-5293-4

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
22018-07-20full-release2026-05-31 20:26:01

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 16 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL, METERED / TOPICAL525 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SPONGE / TOPICAL4 %w/wExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SOLUTION / TOPICAL40 %w/vExact identifier — unii+route
14 equally ranked IID candidates
pine needle oil (pinus sylvestris)PINE NEEDLE OIL (PINUS SYLVESTRIS)5EXL5H740YLOTION / TOPICAL0.25 %w/wExact identifier — unii+route+dosage form
2 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302OIL / TOPICAL72 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL / TOPICAL75 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SWAB / TOPICAL43.9 %w/wExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SPONGE / TOPICAL4 %w/wExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SWAB / TOPICAL43.9 %w/wExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302SOLUTION / TOPICAL40 %w/vExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302OIL / TOPICAL72 mgExact identifier — unii+route
14 equally ranked IID candidates
pine needle oil (pinus sylvestris)PINE NEEDLE OIL (PINUS SYLVESTRIS)5EXL5H740YLOTION / TOPICAL0.25 %w/wExact identifier — unii+route+dosage form
2 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL, METERED / TOPICAL525 mgExact identifier — unii+route
14 equally ranked IID candidates
isopropyl alcoholISOPROPYL ALCOHOLND2M416302GEL / TOPICAL75 mgExact identifier — unii+route
14 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A091559-001MALATHIONMALATHION0.5%LOTION / TOPICALRS2012-05-23

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23c2088c7a36db…
2026-09-14 22:38:342026-08A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2384e616aacf4f…
2026-08-18 06:07:402026-07A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2331067a03dcf5…
2025-08-23 18:47 UTC2025-08A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-236a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-232680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-235bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-231e350fbaab3a…
2024-05-31 18:47 UTC2024-05A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-238072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-235c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-235d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-234b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2374a2ff9319b5…
2022-03-09 01:35 UTC2022-03A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-2387673890dc5c…
2021-03-12 10:30 UTC2021-03A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-235aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-238869cabd3fbd…
2020-11-12 02:37 UTC2020-11A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23c0c555d07b60…
2019-12-14 00:12 UTC2019-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-233f01610625f2…
2019-09-15 20:21 UTC2019-09A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23b00525d2431f…
2019-07-19 19:46 UTC2019-07A091559-001MALATHION0.5%LOTION / TOPICALAT2012-05-23ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-236a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-231c564ffb4f44…
2023-12-20 04:57 UTC2023-12A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-239b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-233f0d92c62455…
2023-05-13 08:27 UTC2023-05A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-23053a50430f4f…
2023-01-26 05:58 UTC2023-01A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-233bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A091559-001MALATHION0.5%LOTION / TOPICALRS2012-05-233a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-07-19 19:46 UTC2019-07A091559-001AT1ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OvideMALATHIONSun Pharmaceutical Industries, Inc.945f46fa-4b79-49fd-a890-477f251e21642026-07-15Warnings, Adverse reactionsExact identifier
ndc (package): 51672-5293-4
ndc (product): 51672-5293
ndc11 (package): 51672529304
spl id: 56a7269a-5153-0a24-e063-6294a90a12b2
spl set id: 945f46fa-4b79-49fd-a890-477f251e2164

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.